On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...
An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.
RBC Capital analyst Brian Abrahams raised the firm’s price target on Gilead (GILD) to $84 from $81 but keeps a Sector Perform rating on the ...
RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.
Zacks.com on MSN14h
Eyenovia Stock Tumbles on Termination of Phase III Myopia StudyEyenovia, Inc. EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, ...
GlobalData on MSN14h
Gilead’s Livdelzi shows promise in PBC clinical trialThe analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...
This report explores the benefits and challenges of NHS-industry partnerships aiming to catalyse improvements in the health ...
Echo IQ executive chair Andrew Grover is generally cheerful and optimistic, but wasn't in the weeks leading up to the US regulator’s approval of its artificial intelligence-based aortic stenosis (AS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback